Skip to main content
. 2020 May 8;12(5):519. doi: 10.3390/v12050519

Figure 5.

Figure 5

The effect of TRiC/CCT inhibitor HSF1A on ZIKV propagation. (a) HeLa cells treated with HSF1A (0, 25, 50, 75, or 100 µM) or DMSO (control) for 48 h, after which lactate dehydrogenase (LDH) released in the supernatants was assayed. (b) HeLa cells were pretreated with HSF1A (0, 50, or 100 µM) for 12 h and infected with ZIKV at MOI of 1. Infected cells were maintained in media containing HSF1A (0, 50, or 100 µM). At the indicated timepoints post infection (0, 12, 24, and 36 h), whole-cell lysates were harvested and analyzed by immunoblotting with indicated antibodies. β-actin was used as a loading control. Red arrow shows detected NS1 protein. (c) HeLa cells were pretreated with HSF1A (0, 25, 50, 75, or 100 µM) for 12 h and infected with ZIKV at MOI of 0.1. Supernatants were harvested and titrated at 36 h post infection by plaque assay. * p < 0.05 and ** p < 0.01 by one-way ANOVA with Dunnet’s multiple comparisons test. Data are plotted as the mean ± SEM.